CDK Inhibitor Pushes Syros Pharma (SYRS) Into Positive Territory; Mondelez Intl (MDLZ) Stops Merger with Hershey (HSY)


Shares of Syros Pharmaceuticals, Inc. (Nasdaq:SYRS) climbed over 8% in after-hours trading Monday as the company said that a research (published online) from its scientific founders Nathanael Gray and Richard Young suggest that its compound THZ531 – a selective CDK12 and CDK13 inhibitor – could be effective as a monotherapy and as a combination therapy in a range of cancers

SYRS stock finished the regular session at $11.70, down $0.05 (or -0.43%) with a total volume of 34,920 shares traded

Syros Pharmaceuticals, which focuses on developing treatments for cancer and immune-mediated diseases, has 23.37M Shares Outstanding and SYRS stock 52-year range is between $8.16 and $21.50 per share. At close on Monday, the biopharmaceutical company had a Market Capitalization of $274.65M



Mondelez International, Inc. (Nasdaq:MDLZ) shares surged more than 3% in the extended session Monday after the company said that it has determined to cease discussions with Hershey Co. (NYSE:HSY) regarding a potential business combination transaction between the companies

MDLZ stock closed in negative territory by 0.05% (or -$0.02) at $43.04, and 4.38M of its shares changed hands during the day

Mondelez International, which manufactures and markets snack food and beverage products worldwide, has 1.56B Shares Outstanding, Market Capitalization (intraday) of $66.95B and MDLZ stock one-year range is from $35.88 to $47.42 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at